Biomea Fusion
Market cap $35.5M 72.7M shares (10-Q, Oct 29, 2026) × $0.488 close Nov 17, 2026
Most recent annual filing: 2026-03-24
- Icovamenib topline1Q 2027Icovamenib topline, 1Q 2027, thesis-defining
- Icovamenib COVALENT-211 topline1Q 2027Icovamenib COVALENT-211 topline, 1Q 2027, thesis-defining
- Biomea Fusion corporate financing1Q 2027Biomea Fusion corporate financing, 1Q 2027, routine
- Icovamenib COVALENT-212 topline2Q 2027Icovamenib COVALENT-212 topline, 2Q 2027, major
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (4 active programs)
BMF-650
BMF-500
icovamenib
Discontinued (1)
- icovamenib — Type 1 Diabetes · topline results reported from COVALENT-112 in April 2026; no ongoing trials in type 1 diabetes as of filing date
Capital (as filed)
- Cash
- $26.4M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Operating cash flow
- −$8.4M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $26.8M cash, runway into the second quarter of 2027 per the update of Nov 10, 2026 — the company's own words as read there, not the filed figure
Offering documents (1)
- 2026-09-22 424B5 · Preliminary prospectus
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (10)
- 2026-11-11 UPDATE: Biomea Fusion (BMEA) - Q3 Status Check: The Runway Held, the Price Didn’t 🔒 Paid
- 2026-10-15 UPDATE: Biomea Fusion (BMEA) - The Deck Said the Quiet Part 🔒 Paid
- 2026-10-14 UPDATE: Biomea Fusion (BMEA) - The Financing Print Came Back Quiet ★ Distilled Pro
- 2026-09-23 UPDATE: Biomea Fusion (BMEA) - The Raise Landed Before the Data 🔒 Paid
- 2026-09-23 UPDATE: Biomea Fusion (BMEA) - The Raise That Didn’t Land 🔒 Paid
- 2026-08-24 UPDATE: Biomea Fusion (BMEA) - “Near Completion” Became “Completed” 🔒 Paid
- 2026-08-06 UPDATE: Biomea Fusion (BMEA) - The Catalysts Moved Past the Cash 🔒 Paid
- 2026-06-08 UPDATE: Biomea Fusion (BMEA) - The ADA Receipts and the Quiet Catalyst Slip 🔒 Paid
- 2026-04-28 UPDATE: Biomea Fusion (BMEA) - The Zombie Trial Wakes Up 🔒 Paid
- 2026-04-04 Biomea Fusion (BMEA) - Scientific Deep Dive for Icovamenib and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (10 calls)
Every verdict Biotech Distilled has published on Biomea Fusion, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-04-04 Watch Biomea Fusion (BMEA) - Scientific Deep Dive for Icovamenib and Pipeline Products Compelling menin-inhibition science and oral GLP-1 pipeline are offset by a going-concern balance sheet and near-certain dilutive raise, warranting a wait-for-the-raise stance.
- 2026-04-28 Speculative buy speculative UPDATE: Biomea Fusion (BMEA) - The Zombie Trial Wakes Up COVALENT-112 T1D data showed durable C-peptide increases in two indications, widening icovamenib's optionality, though the balance sheet remains terrifying and a dilutive raise is still the base case.
- 2026-06-08 Speculative buy speculative UPDATE: Biomea Fusion (BMEA) - The ADA Receipts and the Quiet Catalyst Slip ADA data de-risked liver safety and confirmed a 1.8% placebo-adjusted HbA1c receipt in GLP-1 non-responders, but BMF-650 slipped to Q3 and the liquidity event likely precedes the data catalyst.
- 2026-08-06 Speculative buy speculative UPDATE: Biomea Fusion (BMEA) - The Catalysts Moved Past the Cash Both Phase IIb T2D readouts slipped into 2027 while cash runs out in the same quarter as the first readout, making this a downgrade on timing and financing sequencing rather than biology.
- 2026-08-24 Speculative buy speculative UPDATE: Biomea Fusion (BMEA) - "Near Completion" Became "Completed" COVALENT-211 fully enrolled at n=64 with a placebo-controlled design and Q1 2027 date now operationally supported, but financing sequencing and going-concern remain unchanged.
- 2026-09-23 Speculative buy speculative UPDATE: Biomea Fusion (BMEA) - The Raise Landed Before the Data The underwritten offering launched ahead of BMF-650 data with a demand-constrained structure, but the science and COVALENT-211 readout are unchanged; the pricing print is what matters.
- 2026-09-23 Watch UPDATE: Biomea Fusion (BMEA) - The Raise That Didn't Land The offering was terminated with no shares sold, leaving the going-concern gap open and now public, with all weight on the October BMF-650 print to enable a better-priced raise.
- 2026-10-14 Watch UPDATE: Biomea Fusion (BMEA) - The Financing Print Came Back Quiet BMF-650 Phase 1 showed clean tolerability but only 1.5–3.2% outpatient weight loss at or below the class benchmark, failing to reopen the financing window; icovamenib thesis intact but standing aside until a raise is priced.
- 2026-10-15 Avoid UPDATE: Biomea Fusion (BMEA) - The Deck Said the Quiet Part The BMF-650 slide deck revealed suspected dosing non-compliance in the top-dose cohort, weakening the licensing pitch; stock fell below $1 with a going-concern warning and no partner, making the next raise very expensive.
- 2026-11-11 Avoid UPDATE: Biomea Fusion (BMEA) - Q3 Status Check: The Runway Held, the Price Didn't Q3 10-Q kept runway into Q2 2027 on $26.8M cash but no financing or license was priced, stockholders' equity collapsed to $7.6M, and the stock sub-$1 means any raise is severely dilutive.
- Long call · opened Apr 28, 2026 at $1.53 · closed Sep 24, 2026 (downgraded to WATCH from long) at $1.49 · -2.6% vs XBI +19.0%
- Avoid call · opened Oct 15, 2026 at $0.836 · -41.6% vs XBI -3.0% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (7 quotes from 6 filings)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“As of September 30, 2026 icovamenib is now being evaluated across two ongoing Phase II clinical trials (COVALENT-211 and COVALENT-212) in type 2 diabetes, with the primary 26-week HbA1c endpoint readout from our Phase II clinical trial (COVALENT-211) expected in the first quarter of 2027, and the corresponding 26-week primary endpoint HbA1c readout from our Phase II clinical trial (COVALENT-212), expected in the second quarter of 2027.”
matched to Icovamenib (COVALENT-211) · topline data / matched to Icovamenib (COVALENT-212) · topline data
-
-
-
“Our Phase I GLP-131 trial for BMF-650 in obese, otherwise healthy volunteers is ongoing, with topline results expected in the third quarter of 2026.”
matched to BMF-650 · topline data
-
-
-
“Phase I GLP-131 (BMF-650) obesity clinical trial on track with initial 28-day weight reduction data expected in the third quarter of 2026”
matched to BMF-650 · topline data / matched to Icovamenib (COVALENT-212) · topline data
-
-
-
“Our Phase I GLP-131 trial for BMF-650 in obese, otherwise healthy volunteers is ongoing, with topline results expected in the third quarter of 2026.”
matched to BMF-650 · topline data -
“Phase I GLP-131 (BMF-650) obesity clinical trial on track with initial 28-day weight reduction data expected in the third quarter of 2026”
matched to BMF-650 · topline data
-
-
-
“Comprehensive dataset to be presented at the American Diabetes Association’s (ADA) Scientific Sessions (abstract is preliminary until time of presentation; full release scheduled for June 5, 2026 at 6:30 pm CDT).”
matched to Icovamenib (COVALENT-212) · topline data
-
-
-
“Comprehensive dataset to be presented at the American Diabetes Association’s (ADA) Scientific Sessions (abstract is preliminary until time of presentation; full release scheduled for June 5, 2026 at 6:30 pm CDT).”
matched to Icovamenib (COVALENT-211) · topline data / matched to Icovamenib (COVALENT-212) · topline data
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (29)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 5, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 10, 2026ReleaseBiomea Fusion Reports Third Quarter 2026 Financial Results and Corporate Highlights→ BD updateSummary on the 8-K
- Nov 10, 2026ReleaseBiomea Fusion Announces Poster Presentation of Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist, at ObesityWeek® 2026→ BD updateSummary on the 8-K
- Nov 10, 20268-KCurrent report · EX-99.1→ BD updateThe Q3 10-Q lands with $26.8M cash, a formal going-concern warning that now explicitly states the company cannot fund twelve months of operations, and a stock sitting at $0.55 — well below Nasdaq's $1.00 minimum bid threshold. The menin brake thesis is intact heading into the Q1 2027 COVALENT-211 readout, but the cost of capital to get there has never been higher.
- Nov 10, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Oct 14, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1→ BD updateThe market delivered its verdict on the BMF-650 data overnight — BMEA cratered 33.8% in Tuesday's session, a drop the October 13 post flagged as still pending. The full slide deck adds new detail: a human peak-to-trough ratio of 1.7, a competitive GI tolerability chart that looks favorable, and explicit next-steps language pointing to partnership/licensing rather than independent Phase 2 — confirming the thesis shift from "buyout bait" to "licensing asset."BD extracted 1 program update from this document → BMEA pipeline
- Oct 13, 2026ReleaseBiomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist→ BD updateBMF-650's Phase 1 data is in: clean tolerability, a one-step titration path to 400 mg, but outpatient weight loss of 1.5–3.2% that trails the oral GLP-1 field benchmark — and the company is now explicitly shopping the asset for a partnership rather than developing it alone.BD extracted 1 program update from this document → BMEA pipeline
- Oct 12, 2026ReleaseBiomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist
- Sep 23, 2026ReleaseBiomea Fusion Announces Termination of Proposed Public Offering of Securities→ BD updateThe offering Biomea announced yesterday was pulled this morning — management couldn't get terms it liked, no cash was raised, and the going-concern clock is now ticking louder than ever with both Phase IIb readouts at or past the cash horizon.
- Sep 22, 2026ReleaseBiomea Fusion Announces Proposed Public Offering of Securities→ BD updateSummary on the 8-K
- Sep 22, 20268-KCurrent report: other events→ BD updateThe dilution event the thesis predicted since the deep dive is officially here — Biomea has launched an underwritten public offering today, and the 8-K simultaneously revealed BMF-650 weight data is now expected in October 2026, not "Q3," meaning the financing catalyst and the data catalyst are now landing in the same window.
- Sep 22, 2026424B5Prospectus supplement (offering)→ BD updateSummary on the 8-K
- Sep 3, 2026ReleaseBiomea Fusion to Participate in Upcoming Investor Conferences
- Aug 24, 2026ReleaseBiomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes→ BD updateCOVALENT-211 just closed enrollment at 64 patients — the "near completion" watch-list item from the August 5 update is now confirmed, locking in the Q1 2027 readout for the make-or-break T2D trial and setting a year-end target for COVALENT-212.
- Aug 13, 2026ReleaseBiomea Fusion Announces First Patient Dosed in OPAL Study Evaluating Icovamenib in Combination with Semaglutide in Obesity
- Aug 5, 2026ReleaseBiomea Fusion Reports Second Quarter 2026 Financial Results and Corporate HighlightsBD extracted 1 program update from this document → BMEA pipeline
- Aug 5, 20268-KCurrent report · EX-99.1
- Aug 5, 202610-QQuarterly reportBD extracted 1 program update from this document → BMEA pipeline
- Jun 11, 20268-KCurrent report: shareholder vote
- Jun 5, 2026ReleaseBiomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 StudyBD extracted 1 program update from this document → BMEA pipeline
- Jun 3, 2026ReleaseBiomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in ObesityBD extracted 1 program update from this document → BMEA pipeline
- May 12, 2026ReleaseBiomea Fusion to Participate at Upcoming Investor Conferences
- May 11, 2026ReleaseBiomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights
- May 11, 20268-KCurrent report: results of operations · EX-99.1
- May 11, 202610-QQuarterly report
- May 5, 2026ReleaseBiomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions
- Apr 28, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1
- Apr 27, 2026DEF 14AProxy statement
- Mar 24, 20268-KCurrent report: results of operations · EX-99.1
- Mar 24, 202610-KAnnual report
1 more filing (13G holder notices, S-8, proxy material, SEC correspondence …)
- Apr 27, 2026ARSAnnual report to shareholders